Study of Detection of lasB gene and its Phenotypic Expression in Pseudomonas aeruginosa Obtained From Various Clinical Samples
Background: Pseudomonas aeruginosa is amongst the top listed pathogens responsible for health care related infection and the third most common co-infecting pathogen among COVID-19 patients. P.aeruginosa can affect immunocompromised patients. A major problem in infections caused by P.aeruginosa is high and multi-drug resistance to antibiotics commonly used to treat the patients. P.aeruginosa produces cellular and extracellular virulent factors.The elastase enzyme encoded by lasB gene is a major virulence factor secreted by P.aeruginosa that contributes in pathogenicity. In India, few researchers have focussed on virulence lasB gene and its allied virulence factor elastase B in P.aeruginosa. Therefore, this study was planned to study detection and phenotypic expression of lasB genes in P. aeruginosa clinical strains.
Materials and methods: This research study included 30 strains of P. aeruginosa obtained from various clinical samples. Screening of elastase B production was studied on nutrient agar media containing 1% elastin in 0.1 M tris buffer (pH 8.0), 0.04 M CaCl2, and 0.03 M tris buffer (pH.8.0) and geneslasBwere detected by polymerase chain reactions and gel electrophoresis technique.
Results: Polymerase chain reaction amplification results showed presence of lasB genes in 23 (76.67%) out of 30 P.aeruginosa strains and 18 (60%) of the isolates showed elastase B production.
Conclusion: Gene lasB in P. aeruginosa is one of the major virulent factors and contributes in causation of disease. It is concluded that lasB gene can be a notable virulent factor shown by presence of 76.67% and expressed phenotypically by 60% of P. aeruginosa strains. The specified key role of lasB virulent gene in the development of disease would help in determining idea of the prognosis of infections caused by P.aeruginosa and understanding successful treatment plan and designing ideal vaccine against the prevention of P.aeruginosa infection.
2. Jiuxin Qu, Zhao Cai, Yumai Liu et al.Persistent Bacterial Coinfection of a COVID-19 patient caused by Pseudomonas aeruginosa chronic colonizer.Front.Cell.Infect.Microbiol. March, 2021.
3. Al-Obaidi RD, Al-Dahmoshi HOM. Biofilm and antibiotic resistance profile among Pseudomonas aeruginosa isolated from clinical samples. Eurasia J Biosci .2020;14: 1135-1139
4. Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019; 6: 109–19
5. Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res. 2019.
6. Askoura M, Mottawea W, Abujamel T, Taher I. Effl ux pump inhibitors (EPIs) as new antimicrobialagents against Pseudomonas aeruginosa. Libyan J Med. 2011; 6: 5870
7. Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 1989; 140:1650-61
8. Doring G. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients. In:Campa M, Bendinelli M, Friedman H (eds) Pseudomonas aeruginosa as an opportunistic pathogen.New York, NY, Plenum Press. 1993: 245-73
9. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol.2006; 55: 1619–1629
10. Fluit AC, Verhoef J, Schmitz FJ, The European sentry participants. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. Microbiol Dis. 2000; 19:370-74
11. Preeti BM, Manjanath PS. Antimicrobial susceptibility pattern of aeruginosa from clinical isolates at atertiary care centre of in Jivaypur Karna.Journal of Chemical and Pharmaceutical Research. 2015; 7(8):186-9
12. Charles D. Morin, Eric Déziel, Jeff Gauthier, Roger C. Levesque & Gee W. Lau. An Organ System-Based Synopsis of Pseudomonasaeruginosa Virulence.2021.12:1, 1469-1507
13. Alhazmi A. Pseudomonas aeruginosa – pathogenesis and pathogenic mechanisms.Int J Biol.2015; 7: 44–67
14. Sabharwal N, Dhall S, Chhibber S, Harjai K. Molecular detection of virulence genes as markers in Pseudomonas aeruginosa isolated from urinary tract infections. Int Mol Epidemiol Genet. 2014; 5: 125–134
15. Yahr TL, Hovey AK, Kulich SM, Frank DW.Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene. J Bacteriol. 1995; 177:1169 – 78
16. Jaffar-Bandjee MC, Lazdunski A, Bally M,Carrere J, Chazalette JP, Galabert C.Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J Clin Microbiol. 1995; 33:924–29
17. Van-Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections.EmergInfectDis. 1998; 4:551–60
18. Morihara, K. Pseudomonas aeruginosa proteinase. I.Purification and general properties. Biochim. Biophys. Acta.1963; 73:113-124
19. Heck, L. W., K. Morihara, and D. R. Abrahamson.Degradation of soluble laminin and depletion of tissue associated basement membrane laminin by Pseudomonas aeruginosa elastase and alkaline protease. Infect.Immun.1986; 54:149-153
20. Schultz, D. R., and K. F. Miller.Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect.Immun.1974; 10:128-135
21. Kapur, Shrinivas. Protease and elastase production by P. aeruginosa.Eur J Epidemiol
22. Cotar AI, Chifiriuc MC, Banu O, Lazer V. Molecular Characterizationof Virulence Patterns in Pseudomonas aeruginosa strains isolatedfrom respiratory tract and wound sample. Int J Mol EpidemiolGenet.2014; 3:125-134
23. Fritsch EFTM, Sambrook J. Molecular cloning-a laboratory manual, 7th edition, Cold SpringHarbor Laboratory, Principles of Gene Manipulation.
24. Ertugrul BM, Erman Oryasin, Lipsky BA, Willke A, Bozdogan B. Virulence genes fliC, toxA and phzS are common among Pseudomonas aeruginosa isolates from diabetic foot infections. Infectious Disease. 2017; 50 (4):273–9
25. Josh Suna, Doris L. LaRockc et al. The Pseudomonas aeruginosa protease LasB directly activates IL-1b; 2020; doi:10.1016/j.ebiom.2020.102984.
26. Cigana C, Castandet J, Sprynski N et al. Pseudomonas aeruginosa Elastase Contributes to the Establishment of Chronic Lung Colonization and Modulates the Immune Response in a Murine Model. Front. Microbiol.2021;11:620819.doi:10.3389/fmicb.2020.620819
27. Dulon S, Leduc D, Cottrell GS, D´Alayer J, Hansen KK, Bunnett NW,et al. Pseudomonas aeruginosa elastase disable proteinase-Activated Receptor 2 in respiratory epithelial cellls.Am J Resp Cell Mol Biol.2005; 32:411–19
28. Mitov I, Strateva T, Markova B. Prevalence of Virulence Genes Among Bulgarian Nosocomial and Cystic Fibrosis Isolates of Pseudomonas aeruginosa. Braz J Microbiol. 2010; p. 588–95
29. Espinosa MR, Gloria SC, Gabriela DS, Luisa SM, J L Mendez EA.Genetic and Phenotypic Characterization Of Pseudomonas aeruginosa Population With High Frequency Of Genomic Islands. Plos one.2012; 7:1–11
30. Das R, Sinha P, Kar D. Characterization of lasB and plcH Gene FromPseudomona aeruginosa Isolates in Silchar.Clin Microbiol.2016;5: 239.
31. Birret A, Cripps AW. The Immunoreactive activities of Pseudomonasaeruginosa: relevance for cystic fibrosis. Am Rev Respir Dis. 1993; 148:793–804
32. Peters JE, Park SJ, Darzins A, Freck LC, Saulnierand JM, Wallach JM,et al. Further studies on Pseudomonas aemginosa LasA: analysis ofspecificity.Mol Microbiol.1992; 6:1155-62.
33. Galloway DR. Pseudomonas aeruginosa elastase and elastdysis revisited: recent developments. Mol Microbiol. 1991; 5:2315–21.
Copyright (c) 2021 Jagannath D. Andhale, R.N Misra
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.